Table 1 Baseline Demographics and Disease Characteristics.
Variable | N (%) or median (range) |
|---|---|
Age | 62 years (35–68) |
Sex, female | 13 (52%) |
Race | |
White | 18 (72%) |
Black or African American | 3 (12%) |
Asian | 2 (8%) |
Other or not known | 2 (8%) |
ISS stage | |
1 | 6 (24%) |
2 | 10 (40%) |
3 | 6 (24%) |
Not known | 3 (12%) |
High-risk cytogeneticsa | 12 of 21 (57%) |
Renal insufficiency at diagnosis | 7 (28%) |
ECOG performance status | |
0 | 14 (56%) |
1 | 9 (36%) |
2 | 2 (8%) |
Co-morbidities | |
Prior cancer treated with systemic chemotherapy and/or radiation before diagnosis of active myeloma | 6 (24%) |
Diabetes mellitus | 5 (20%) |
Hypertension | 7 (28%) |
Cardiovascular disease (coronary artery disease, heart valve disease, arrythmias, peripheral vascular disease) | 3 (12%) |
Induction chemotherapy before ASCT | |
Induction chemotherapy: b | |
Bortezomib, lenalidomide, dexamethasone (VRD) | 17 (68%) |
Daratumumab + VRD | 6 (24%) |
Cyclophosphamide, bortezomib, dexamethasone (CyBorD) | 2 (8%) |
Duration of induction chemotherapy | 4 months (3–6) |
AntiCD38 antibody exposure | 6 (24%) |
Lenalidomide exposure | |
N | 23 patients (92%) |
Cycles | 5 cycles (1–8) |
Cyclophosphamide exposure | 5 (20%) |
More than 2 months of cyclophosphamide exposure | 4 (16%) |
Lines of therapy before mobilization | |
1 | 22 (88%) |
2 | 3 (12%) |
Radiation for multiple myeloma | |
N | 5 (20%) |
Dose (median, range) | 2000 cGY (800-3000) |
Best response prior to mobilization, VGPR or better | 22 (88%) |
